Activating NK Cell Receptors as Trigger Molecules for Bispecific Antibodies to Enhance Anti-Tumour NK Cell Responses
- Evaluating preclinical case studies of NKG2D or NKp30 engaging bispecific antibodies
- Synergy with FcγRIIIA engagement – discussing multispecific molecules and impact of molecule architecture vs combination approaches to improve synapse quality and PK profile
- Exploring opportunities for combination with adoptive NK cell transfer using a novel NK cell expansion technology for enhanced therapeutic impact